BlackRock, Inc. 13D and 13G filings for PMV Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-07-08 4:32 pm Sale | 2024-06-30 | 13G | PMV Pharmaceuticals, Inc. PMVP | BlackRock Inc. BLK | 1,162,193 2.300% | -2,067,604 (-64.02%) | Filing |
| 2024-01-29 3:26 pm Sale | 2023-12-31 | 13G | PMV Pharmaceuticals, Inc. PMVP | BlackRock Inc. BLK | 3,229,797 6.300% | -1,447,231 (-30.94%) | Filing |
| 2023-07-07 4:35 pm Purchase | 2023-06-30 | 13G | PMV Pharmaceuticals, Inc. PMVP | BlackRock Inc. BLK | 4,677,028 10.200% | 1,225,661 (+35.51%) | Filing |
| 2023-01-31 1:58 pm Purchase | 2022-12-31 | 13G | PMV Pharmaceuticals, Inc. PMVP | BlackRock Inc. BLK | 3,451,367 7.600% | 911,543 (+35.89%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | PMV Pharmaceuticals, Inc. PMVP | BlackRock Inc. BLK | 2,539,824 5.600% | 2,539,824 (New Position) | Filing |